PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Projekt

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Abgeschlossen · 2012 bis 2017

Müller Rüdiger, Forrer Silvia

Art

Klinische Forschung

Reichweite

Multizentrisch, KSSG als teilnehmendes Zentrum

Bereiche

Rheumatologie

Status

Abgeschlossen

Start

2012

Ende

2017

Finanzierungsart

Industrie

Studiendesign

Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment

Webseite

http://clinicaltrials.gov/ct2/show/NCT01212770

Kurzbeschreibung/Zielsetzung

Official Title:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Two Doses Of Apremilast (CC-10004) In Subjects With Active Psoriatic Arthritis And A Qualifying Psoriasis Lesion

Purpose:
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis and a qualifying psoriasis lesion.

Apremilast is proposed to improve signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.